The Claim
In ZSF1 obese rats with HFpEF, administration of low-dose semaglutide (30 nmol/kg twice weekly for 16 weeks) significantly reduces cardiac and hepatic fibrosis, as measured by picrosirius red staining and transcriptomic downregulation of collagen genes, independent of weight loss.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese rats with heart failure and preserved ejection fraction, a specific low dose of semaglutide given twice weekly for 16 weeks reduces scarring in the heart and liver, measured by collagen staining and reduced collagen gene activity, without changes in body weight.
See the scientific wording
In ZSF1 obese rats with HFpEF, low-dose semaglutide (30 nmol/kg twice weekly for 16 weeks) significantly reduced cardiac and hepatic fibrosis, as measured by picrosirius red staining and transcriptomic downregulation of collagen genes, independent of weight loss.
A signaling molecule binds to receptors on heart and liver cells, turning down genes that make scar tissue and turning up genes that break down fats and sugars. This reduces fat buildup and stiffening in both organs without changing body weight.
What the research says
1 studyIn rats with heart and liver problems, a small amount of a diabetes drug called semaglutide helped reduce scarring in both organs—even though the rats didn’t lose weight. This suggests the drug works directly on the scarring process, not just by making animals thinner.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.